CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Ipsen sends clear Memo to rare diseases with up to $796M buyout

Positive
AI Analysis

Summary

Ipsen is acquiring Memo Therapeutics in a deal valued at up to $796 million, securing a midstage monoclonal antibody for rare diseases treatment.

Importance:7/10
Sentiment:
0.60
acquisitionrare diseasesmonoclonal antibodyMemo Therapeutics
Related Companies

Read the original article

Published by BioSpace on July 1, 2026 2:24 PM

Read Original